In this edition of HCPLive’s newsletter on monthly US Food and Drug Administration (FDA) news, we cover updates from across therapeutic pipelines in December.

FDA Reopening Comment Period on Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products

Attention all pet parents!

For decades, food makers have been allowed to declare an ingredient safe without ever telling the FDA — and the agency had no way to track what chemicals were entering the food supply. A new proposed rule would end that voluntary loophole, though critics note companies can still bring products to market before any federal review takes place. The fight over what's really in your food is just getting started.

The FDA just issued six more fast-track review vouchers, instantly accelerating drug approvals for 15 companies and sending shockwaves through pharmaceutical innovation, investment decision-making, and patient access to game-changing therapies.The Fast-Track Voucher: A Critical Catalyst for Innovati

BTIG reiterated Buy on Apr 7, 2026 after Climb Bio received FDA Fast Track designation in early April 2026; regulatory acceleration alters timelines and investor expectations.

FDA accepted BioXcel's IGALMI filing on Apr 1, 2026; review enters a 6–10 month window per FDA timelines and creates defined near-term catalysts.

A pair of sweeteners are being recalled nationwide due to a labeling mishap, according to the Food and Drug Administration (FDA).

The FDA just issued six more fast-track review vouchers, instantly accelerating drug approvals for 15 companies and sending shockwaves through pharmaceutical innovation, investment decision-making, and patient access to game-changing therapies.The Fast-Track Voucher: A Critical Catalyst for Innovati

Investing.com-- The U.S. Food and Drug Administration is piloting a program to fast-track approval of nicotine pouches from four major tobacco companies, in a move that could reshape the booming market for smoke-free alternatives, Reuters reported on Monday, citing meeting transcripts. The FDA plans to complete reviews of products from Philip Morris International Inc (NYSE:PM), Altria (NYSE:MO), Reynolds American -- part of British American Tobacco (LON:BATS) -- and Turning Point Brands (NYSE:TPB) by December, far quicker than the years-long process companies have faced, Reuters reported. Earlier this year, the agency cleared 20 Philip Morris pouches under its Zyn label after a five-year wait. Products in the pilot include an updated version of Zyn, called Zyn Ultra, as well as Altria’s on! Plus, Reynolds’ Velo mini, and Turning Point’s Fre and Alp. For items already sold without FDA clearance, approval would remove legal risks and potential enforcement, the report said. The initiative comes amid pressure from the Trump administration to accelerate authorizations and follows heavy industry lobbying. Nicotine pouches, inserted under the lip, are the fastest-growing U.S. tobacco category, the report added. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for BATS plus thousands of other stocks and find your next hidden gem with massive upside.

Investing.com -- Amphastar Pharmaceuticals (NASDAQ:AMPH) stock gained 4% after the company announced FDA approval for its generic version of iron sucrose injection, a treatment for iron deficiency anemia in patients with chronic kidney disease. The newly approved product, previously referred to as AMP-002, will be available in three dosage forms: 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vials. Amphastar plans to launch the product in the third quarter of 2025. "We are delighted to announce the FDA approval of our generic iron sucrose injection," said Dr. Jack Zhang, Amphastar’s President and Chief Executive Officer. "This approval, once again, demonstrates our dedication to developing complex generics and leveraging cutting-edge, in-house manufacturing expertise to produce both active pharmaceutical ingredients and finished drug products under the highest regulatory standards in the U.S." The approval represents a significant opportunity for Amphastar, as the reference product Venofer® generated approximately $513 million in U.S. sales for the 12 months ended June 30, 2025, according to IQVIA data. Amphastar’s pipeline includes three ANDAs and one biosimilar insulin candidate currently under FDA review, targeting products with a combined market size exceeding $2.5 billion. The company is also developing three biosimilar products targeting a market exceeding $6 billion and two generic products aimed at a market of over $1 billion. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if AMPH is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Investing.com -- Argenx NV ADR (NASDAQ:ARGX) stock tumbled 6% after the U.S. Food and Drug Administration (FDA) identified a potential serious risk associated with the company’s lead drug, Vyvgart. The FDA published a report highlighting a "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy" as a potential signal of serious risk with Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection. The regulatory agency stated it is currently evaluating the need for regulatory action. Vyvgart is Argenx’s flagship product, approved for treating generalized myasthenia gravis, a rare autoimmune disease. The identification of this safety concern comes at a critical time for the company, which has been positioning the medication as a key growth driver. The FDA regularly monitors approved drugs for potential safety issues that weren’t identified during clinical trials. When a potential signal is detected, the agency conducts further investigation to determine whether regulatory action is warranted, which could range from label updates to more significant restrictions. Investors reacted to the news by selling shares, reflecting concerns about potential impacts on Vyvgart’s commercial prospects should the FDA determine that additional warnings or limitations are necessary. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

FDA Taps Vaxxer Skeptic Vinay Prasad To Oversee Vaccine, Gene Therapy Regulations.